作者：
Margaret L,Weaver [1]
;
Anette Blak,Grossi [2]
;
Jorgen,Schützsack [3]
;
Joanna,Parish [4]
;
Jeanet,Løgsted [5]
;
Ingrid Brück,Bøgh [6]
;
David,Cameron [7]
;
Warren,Harvey [8]
;
Matthias,Festag [9]
;
Noel,Downes [10]
;
Silvana,Venturella [11]
;
Julia,Schlichtiger [12]
;
Sofiene,Mhedhbi [13]
;
Vanessa,Ross [14]
;
Thomas,Kissner [15]
;
Claudia,Stark [16]
;
Stephane,Milano [17]
;
Peter,Heining [18]
;
Manual,Sanchez-Felix [19]
作者单位：
Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA margaret.weaver@novartis.com.
[1]
Ellegaard Göttingen Minipigs A/S, Dalmose, Denmark.
[2]
LEO Pharma A/S, Ballerup, Denmark.
[3]
Covance Laboratories Limited, Harrogate, UK.
[4]
CiToxLAB, Scantox A/S, Lille Skensved, Denmark.
[5]
Novo Nordisk A/S, Gentofte, Denmark.
[6]
Huntingdon Life Sciences, Cambridgeshire, UK.
[7]
Charles River Laboratories, Edinburgh, UK.
[8]
F Hoffman-La Roche Ltd, Roche Innovation Center, Basel, Switzerland.
[9]
Sequani Limited, Herefordshire, UK.
[10]
Research Toxicology Centre S.p.A., Pomezia, Italy.
[11]
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
[12]
Galderma Research & Development, Biot, France (current address Villeneuve Loubet, France).
[13]
Huntingdon Life Sciences, Huntingdon, Cambridgeshire, UK.
[14]
Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
[15]
Bayer HealthCare, Berlin, Germany.
[16]
WIL Research Europe BV, Lyon, France.
[17]
Novartis Institutes for BioMedical Research, Basel, Switzerland.
[18]
Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
[19]
DOI
10.1177/0192623315613088
PMID
26674803
发布时间
2016-12-30
换一批
换一批
